Wilmington, Delaware, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Allied Market Research published a report, titled, "Lipid Nanoparticles Market by Type (Solid Lipid Nanoparticles, Nanostructured Lipid Carriers and Others), Application (Therapeutics and Research), and End User (Pharmaceutical and Biotechnology Companies, Acedemic and Research Institutes and Others): Global Opportunity Analysis and Industry Forecast, 2024-2033". According to the report, the lipid nanoparticles market was valued at $0.9 billion in 2023, and is estimated to reach $3.1 billion by 2033, growing at a CAGR of 13.1% from 2024 to 2033.
Request Sample of the Report on Lipid Nanoparticles Market Forecast 2033 - https://www.alliedmarketresearch.com/request-sample/A323703
Prime determinants of growth
Rising incidence of chronic diseases such as cancer, cardiovascular diseases, and diabetes, expansion of the biopharmaceutical sector, and increasing R&D investments are the major factors that drive the growth of the lipid nanoparticles market growth. However, strict regulatory requirements for the approval of lipid nanoparticle-based drugs restricts the market growth. Moreover, advancements in drug delivery systems offers remunerative opportunities for the expansion of the global lipid nanoparticles market.
Report coverage & details
| Report Coverage | Details |
| Forecast Period | 2024–2033 |
| Base Year | 2023 |
| Market Size in 2023 | $0.9 billion |
| Market Size in 2033 | $3.1 billion |
| CAGR | 13.1% |
| No. of Pages in Report | 220 |
| Segments Covered | Type, Application, End User, and Region. |
| Drivers | Rising incidence of chronic diseases |
| Expansion of the biopharmaceutical sector | |
| Increasing R&D Investments | |
| Opportunity | Advancements in drug delivery systems |
| Restraint | Strict regulatory requirements for the approval of lipid nanoparticle-based drugs |
Want to Explore More, Connect to our Analyst - https://www.alliedmarketresearch.com/connect-to-analyst/A323703
Segment Highlights
The solid lipid nanoparticles segment to maintain its leadership status during the forecast period
By type, solid lipid nanoparticles segment dominated the market share in 2023 as they offer enhanced stability and prolonged drug release compared to other nanoparticle formulations, making them attractive for various pharmaceutical applications. In addition, their biocompatibility and low toxicity profile contribute to their widespread acceptance in drug delivery systems which drive the segment growth. Furthermore, advancements in SLN formulation techniques led to improved encapsulation efficiency and controlled drug release kinetics, further bolstering their appeal.
The therapeutics segment to maintain its leadership status during the forecast period
By application, therapeutics segment dominated the market share in 2023, owing to increase in adoption of lipid nanoparticle-based formulations in drug delivery applications which support the segment growth. Therapeutics leveraging lipid nanoparticles offer enhanced efficacy, improved bioavailability, and targeted delivery of drugs, driving their preference among healthcare providers and patients. In addition, ongoing R&D efforts continue to expand the therapeutic applications of lipid nanoparticles, further bolstering their market presence.
The pharmaceutical & biotechnology companies segment to maintain its leadership status during the forecast period
By end user, pharmaceutical & biotechnology companies segment dominated the market share in 2023 owing to extensive R&D activities conducted by pharmaceutical & biotechnology companies, leading to the development of innovative lipid nanoparticle-based drug delivery systems. In addition, pharmaceutical and biotechnology firms possess substantial financial resources and infrastructure to invest in scaling up production and navigating regulatory pathways for product approvals. Their expertise in drug formulation and delivery further strengthens their competitive advantage. Moreover, strategic collaborations with academic institutions and contract research organizations enable these companies to leverage diverse capabilities and accelerate product development thereby driving the segment growth.
For Purchase Related Queries/Inquiry - https://www.alliedmarketresearch.com/purchase-enquiry/A323703
Regional Outlook
North America to maintain its dominance by 2033
North America is poised to maintain its leadership status in the lipid nanoparticles market throughout the forecast period. This dominance can be attributed to robust investment in R&D, a well-established healthcare infrastructure, and a favorable regulatory environment. In addition, the presence of key market players and academic institutions driving innovation contributes to the region's stronghold. Furthermore, increasing prevalence of chronic diseases, rising demand for targeted drug delivery systems, and growing investments in biotechnology and pharmaceutical sectors bolster market growth in North America.
Key Players
- ABP Biosciences, LLC.
- Merck KGaA
- Cytiva
- CD Bioparticles
- CordenPharma
- Precigenome LLC.
- Beam Therapeutics
- Acuitas Therapeutics
- GENEVANT SCIENCES CORPORATION
- Helix Biotech, Inc.
The report provides a detailed analysis of these key players in the global lipid nanoparticles market. These players have adopted different strategies such as product launch, agreement, acquisition, and others to increase their market share and maintain dominant shares in different regions. The report is valuable in highlighting business performance, operating segments, product portfolio, and strategic moves of market players to showcase the competitive scenario.
Get Customized Reports with your Requirements - https://www.alliedmarketresearch.com/request-for-customization/A323703
Recent Developments in Lipid Nanoparticles Market Worldwide
- In January 2021, Sarepta Therapeutics, Inc. and Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and the industry’s most robust and expansive lipid nanoparticle (LNP) patent estate announced a research collaboration and option agreement for the delivery of LNP-gene editing therapeutics in Sarepta’s pipeline for neuromuscular diseases.
- In February 2022, Sarepta Therapeutics, Inc. and GenEdit, Inc., a developer of genetic medicines that leverage its NanoGalaxyTM polymer nanoparticle platform for tissue-selective delivery, announced a research collaboration and option agreement under which the companies are employing GenEdit’s NanoGalaxy platform and Sarepta’s gene editing technology to develop gene editing therapeutics for the treatment of neuromuscular disease.
- In February 2022, Merck, a leading science and technology company announced the closing of the transaction to acquire Exelead, following regulatory clearances and the fulfillment of other customary closing conditions, for approximately USD 780 million in cash. Exelead, a biopharmaceutical CDMO, specializes in PEGylated products and complex injectable formulations, including Lipid Nanoparticle (LNP) based drug delivery technology, which is key in mRNA vaccines and therapeutics for use in Covid-19 and many other indications.
Trending Reports in Healthcare Industry:
Advanced Wound Care Market - Global Opportunity Analysis and Industry Forecast, 2023-2032
Medical/Diagnostic Imaging Market - Global Opportunity Analysis and Industry Forecast, 2023-2032
Defibrillators Market - Global Opportunity Analysis and Industry Forecast, 2023-2032
AVENUE- A Subscription-Based Library (Premium on-demand, subscription-based pricing model) Offered by Allied Market Research:
AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get an online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports.
Get an access to the library of reports at any time from any device and anywhere. For more details, follow the link: https://www.alliedmarketresearch.com/library-access
About Allied Market Research:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
Contact
David Correa
1209 Orange Street,
Corporation Trust Center,
Wilmington, New Castle,
Delaware 19801 USA.
Toll Free: +1-800-792-5285
Int’l: +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
Web: https://www.alliedmarketresearch.com
Follow Us on: LinkedIn Twitter
